Global Generics Pharma Leader Selects Kneat
Kneat (KSIOF) has secured a Services Agreement with a major European-based multinational generic pharmaceuticals manufacturer to digitalize its drawing management process. The unnamed client, with over 20,000 employees and operations in more than 100 countries, will initially implement Kneat's platform at its largest European manufacturing facility.
The drawing management system will support engineering and validation processes by digitalizing technical drawings, eliminating paper-based errors, maintaining revision traceability, and controlling access. The client has the potential to expand Kneat's usage to streamline all validation workflows across their operations.
Kneat reports strong performance metrics, including a 151% net revenue retention rate as of December 31, 2024, and a 97% customer satisfaction rate rating their support as 'very good' or 'excellent'. The company serves the majority of the top 20 largest life sciences companies globally.
Kneat (KSIOF) ha ottenuto un Accordo di Servizi con un importante produttore multinazionale europeo di farmaci generici per digitalizzare il proprio processo di gestione dei disegni. Il cliente, non nominato, conta oltre 20.000 dipendenti e opera in più di 100 paesi, e implementerà inizialmente la piattaforma di Kneat presso il suo più grande stabilimento produttivo europeo.
Il sistema di gestione dei disegni supporterà i processi di ingegneria e validazione digitalizzando i disegni tecnici, eliminando errori basati su carta, mantenendo la tracciabilità delle revisioni e controllando gli accessi. Il cliente ha il potenziale per espandere l'uso di Kneat al fine di semplificare tutti i flussi di lavoro di validazione nelle proprie operazioni.
Kneat riporta forti metriche di performance, inclusa una retention netta del 151% al 31 dicembre 2024 e un tasso di soddisfazione dei clienti del 97%, valutando il loro supporto come 'molto buono' o 'eccellente'. L'azienda serve la maggior parte delle 20 più grandi aziende di scienze della vita a livello globale.
Kneat (KSIOF) ha asegurado un Acuerdo de Servicios con un importante fabricante multinacional europeo de productos farmacéuticos genéricos para digitalizar su proceso de gestión de dibujos. El cliente, que no se nombra, cuenta con más de 20,000 empleados y operaciones en más de 100 países, e implementará inicialmente la plataforma de Kneat en su mayor instalación de fabricación en Europa.
El sistema de gestión de dibujos apoyará los procesos de ingeniería y validación al digitalizar los dibujos técnicos, eliminando errores basados en papel, manteniendo la trazabilidad de las revisiones y controlando el acceso. El cliente tiene el potencial de expandir el uso de Kneat para agilizar todos los flujos de trabajo de validación en sus operaciones.
Kneat informa métricas de rendimiento sólidas, incluyendo una tasa de retención de ingresos netos del 151% al 31 de diciembre de 2024 y una tasa de satisfacción del cliente del 97%, calificando su soporte como 'muy bueno' o 'excelente'. La empresa atiende a la mayoría de las 20 empresas más grandes de ciencias de la vida a nivel mundial.
Kneat (KSIOF)는 주요 유럽 기반 다국적 제네릭 제약 제조업체와 서비스 계약을 체결하여 도면 관리 프로세스를 디지털화합니다. 이름이 공개되지 않은 이 고객은 20,000명 이상의 직원을 두고 있으며 100개국 이상에서 운영되고 있으며, 처음에는 유럽의 가장 큰 제조 시설에서 Kneat의 플랫폼을 구현할 것입니다.
도면 관리 시스템은 기술 도면을 디지털화하여 종이 기반 오류를 제거하고, 수정 이력을 유지하며, 접근을 제어함으로써 엔지니어링 및 검증 프로세스를 지원합니다. 고객은 Kneat의 사용을 확장하여 모든 검증 워크플로를 간소화할 수 있는 잠재력을 가지고 있습니다.
Kneat는 2024년 12월 31일 기준으로 151%의 순수익 유지율과 97%의 고객 만족도를 보고하며, 고객 지원을 '매우 좋음' 또는 '우수함'으로 평가받고 있습니다. 이 회사는 전 세계 상위 20대 생명과학 회사의 대부분에 서비스를 제공합니다.
Kneat (KSIOF) a conclu un accord de services avec un important fabricant multinational européen de médicaments génériques pour digitaliser son processus de gestion des dessins. Le client, dont le nom n'est pas divulgué, compte plus de 20 000 employés et est présent dans plus de 100 pays, et mettra initialement en œuvre la plateforme de Kneat dans sa plus grande installation de fabrication en Europe.
Le système de gestion des dessins soutiendra les processus d'ingénierie et de validation en digitalisant les dessins techniques, en éliminant les erreurs sur papier, en maintenant la traçabilité des révisions et en contrôlant l'accès. Le client a le potentiel d'étendre l'utilisation de Kneat pour rationaliser tous les flux de travail de validation dans ses opérations.
Kneat rapporte de solides indicateurs de performance, y compris un taux de rétention des revenus nets de 151% au 31 décembre 2024 et un taux de satisfaction client de 97%, évaluant leur support comme 'très bon' ou 'excellent'. L'entreprise sert la majorité des 20 plus grandes entreprises de sciences de la vie dans le monde.
Kneat (KSIOF) hat einen Dienstleistungsvertrag mit einem großen europäisch ansässigen multinationalen Hersteller von Generika abgeschlossen, um seinen Zeichnungsmanagementprozess zu digitalisieren. Der nicht benannte Kunde beschäftigt über 20.000 Mitarbeiter und ist in mehr als 100 Ländern tätig und wird die Kneat-Plattform zunächst in seiner größten europäischen Produktionsstätte implementieren.
Das Zeichnungsmanagementsystem wird die Ingenieur- und Validierungsprozesse unterstützen, indem technische Zeichnungen digitalisiert, papierbasierte Fehler beseitigt, die Überarbeitungsverfolgbarkeit aufrechterhalten und der Zugang kontrolliert wird. Der Kunde hat das Potenzial, die Nutzung von Kneat zu erweitern, um alle Validierungs-Workflows in seinen Betrieben zu optimieren.
Kneat berichtet von starken Leistungskennzahlen, einschließlich einer Netto-Umsatzbindung von 151% zum 31. Dezember 2024 und einer Kundenzufriedenheitsrate von 97%, wobei der Support als 'sehr gut' oder 'ausgezeichnet' bewertet wird. Das Unternehmen bedient die Mehrheit der 20 größten Unternehmen im Bereich Lebenswissenschaften weltweit.
- Secured new contract with major multinational pharma manufacturer
- 151% net revenue retention rate as of December 2024
- 97% customer satisfaction rate
- Potential for contract expansion to additional validation workflows
- Strong market position serving majority of top 20 life sciences companies
- None.
LIMERICK, Ireland, April 09, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a multinational producer of generic pharmaceuticals (“the Company”) has signed a Services Agreement with Kneat to digitalize its drawing management process. Drawing management supports engineering and validation processes by digitalizing and organizing all technical drawings, eliminating paper-based errors, maintaining traceability of revisions, and controlling access.
Headquartered in Europe and operating over a dozen manufacturing facilities around the world, the Company is a leading provider of generic and biosimilar pharmaceuticals to patients in over 100 countries. With more than 20,000 employees, the Company will initially use Kneat for management of all its engineering drawings at its largest manufacturing site in Europe. Subsequently, the Company can leverage Kneat to streamline and automate all its validation workflows, ensuring efficiency, accuracy, data integrity and adherence to good manufacturing practice.
“Today’s announcement adds another global leader to our customer community. It also showcases the versatility of the Kneat platform, which can be leveraged to deliver additional adjacent functions."
- Eddie Ryan, Chief Executive Officer of Kneat
Strong customer retention has emerged as a defining characteristic for Kneat as it has grown over the past ten years to become the validation software of choice for the life sciences industry, serving the majority of the top 20 largest life sciences companies in the world. Net revenue retention, which measures the expansion from existing customers for the previous 12 months, was
About Kneat
Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies show up to
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat’s business development activities, the use and implementation timelines of Kneat’s software within the customer’s validation processes, the ability and intent of the customer to scale the use of Kneat’s software within the customer’s organization, and the compliance of Kneat’s platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties.
Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.
For further information:
Katie Keita, Kneat Investor Relations
P: + 1 902-450-2660
E: investors@kneat.com
FAQ
What is the net revenue retention rate for Kneat (KSIOF) as of December 2024?
How many manufacturing facilities will initially implement Kneat's drawing management system?
What is the customer satisfaction rate for Kneat's (KSIOF) support services?
What specific processes will Kneat's drawing management system digitalize for the new client?
How many countries does Kneat's new pharmaceutical client operate in?
